Items tagged with Drug-resistant TB
Delamanid for extensively drug-resistant tuberculosis (post)
New therapies are needed to address the imminent rise of drug-resistant infections. Delamanid is one of two new drugs approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in the past 40 years. The clinical evaluation of delamanid included a subgroup of patients with extensively drug-resistant tuberculosis (XDR-TB), which is more difficult to treat than MDR-TB. This evaluation provides an opportunity for a post hoc analysis of outcomes.
In the age of travel, tuberculosis knows no borders (post)
The recent episode of an air passenger who travelled from India to the United States, while suffering from extensively drug-resistant tuberculosis (XDR-TB*), has raised a public health scare. The passenger, after landing in Chicago, travelled by car to visit relatives in three states before seeking medical care and being diagnosed with XDR-TB. She has been isolated and is currently on treatment at the US National Institutes of Health. Public health officials are now working to locate everyone who has possibly been exposed to the infection, including fellow air passengers.
IAS 2015: Tuberculosis and poor implementation of proven interventions threaten people with HIV and TB (post)
VANCOUVER, Canada – Isoniazid preventive therapy is as effective in staving off tuberculosis as preemptively treating patients with HIV for tuberculosis, research results released here this morning (July 20) showed. The findings came in one of a series of presentations this morning highlighting challenges posed by tuberculosis to the lives and well-being of people living with HIV, and failures to use proven interventions.
Ambitious new U.S. plan may put hundreds of thousands on MDR-TB treatment (post)
The United States plans to place 360,000 multidrug-resistant tuberculosis patients globally on treatment over the next five years, as part of a national tuberculosis action plan currently under draft. The plan – which is due to be submitted to the White House in September – aims to promote universal MDR-TB treatment, accelerate basic TB research, and strengthen domestic capacity to combat MDR-TB, according to Administration officials who discussed the action plan with stakeholders in July.
UK’s Wellcome Trust to fund Sphaera Pharma’s MDR-tuberculosis drug development (post)
Hyderabad: Sphaera Pharma Pvt. Ltd, a Gurgaon-based drug discovery and development company, on Tuesday (July 21) said UK-based biomedical research charity Wellcome Trust had agreed to fund the development of its new drug to treat multiple drug-resistant tuberculosis (MDR-TB).
Is the world losing the fight against 'superbugs'? (post)
WHO says drug resistant infections are an "increasingly serious threat to global public health".
President Obama working on an Action Plan to stop drug-resistant TB (post)
July 28, 2015--This week RESULTS, along with twelve other leading US and international organizations, sent a letter to President Obama to thank him for initiating the development of a U.S. Government National Action Plan for Combating Multidrug-Resistant Tuberculosis (MDR-TB).
The potential impact of up-front drug sensitivity testing on India’s epidemic of multidrug-resistant tuberculosis (post)
Abstract
A global perspective on pyrazinamide resistance: systematic review and meta-analysis (post)
Abstract
Localized transmission significantly drives MDR-TB epidemic in Peru (post)
Local “hot spots” of increased risk appeared to play a key role in disease transmission during a multidrug-resistant tuberculosis epidemic in Lima, Peru, according to recent data.
Page 18 of 117 · Total posts: 0
←First 17 18 19 Last→